stockportfolio.pro
Stocks / DXCM vs RMD
DXCM vs RMD
DexCom, Inc. and ResMed Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| DexCom, Inc. (DXCM) | ResMed Inc. (RMD) | |
|---|---|---|
| Market cap | $28.6B | $28.0B |
| Revenue (latest FY) | $4.66B | $5.15B |
| Net income (latest FY) | $836.30M | $1.40B |
| Revenue growth (5y CAGR) | 19.3% | 11.7% |
| Net margin | 17.9% | 27.2% |
| Return on equity | 30.5% | 23.5% |
| P/E ratio | 32.4 | 18.6 |
| Dividend yield | — | 1.2% |
| Profitable years (of last 10) | 7 | 10 |
| Positive free cash flow | Yes | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open DXCM — free Open RMD — freeFrequently asked questions
Which is bigger, DXCM or RMD?
DexCom, Inc. is larger by market capitalization — $28.6B versus $28.0B.
Which grows faster, DXCM or RMD?
Over the last five fiscal years, DexCom, Inc. grew revenue faster — 19.3%/yr versus 11.7%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.